Form 8-K Jazz Pharmaceuticals For: Feb 08
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Jazz Pharmaceuticals (JAZZ) PT Lowered to $175 at Oppenheimer as Erwinaze Deal Terminated
February 12, 2019 12:26 PM ESTOppenheimer analyst Esther Rajavelu lowered the price target on Jazz Pharmaceuticals (NASDAQ: JAZZ) to $175.00 (from $180.00) while maintaining a Outperform rating.
The analyst commented, "JAZZ announced the termination of its Erwinaze license agreement with Porton Biopharma Limited (PBL) at the expiration of the current term... More
